Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/05/24
Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks? Gold Mining Play Aris Breaks OutInvestors Business Daily • 03/29/24
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 03/19/24
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?Zacks Investment Research • 03/18/24
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/10/24
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionGlobeNewsWire • 03/09/24
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 03/04/24
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/04/24
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?Zacks Investment Research • 03/01/24
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/01/24
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanGlobeNewsWire • 02/28/24
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/27/24
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 TrialGlobeNewsWire • 01/29/24